Evidence map›Paper›PMID 39816292›Full record

ArticleCureus2024

Successful Sequential Treatment From Remdesivir to Molnupiravir for Prolonged COVID-19 in a Patient With Follicular Lymphoma and Renal Pelvic Carcinoma: A Case Report.

Tomoki Satoh, Kentaro Akata, Kei Yamasaki, Akimasa Tsuruta, Kazuhiro Yatera

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tomoki SatohDepartment of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, JPN.
Kentaro AkataDivision of Infection Control and Prevention, University of Occupational and Environmental Health, Japan, Kitakyushu, JPN.
Kei YamasakiDepartment of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, JPN.
Akimasa TsurutaDepartment of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, JPN.
Kazuhiro YateraDepartment of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 69-year-old Japanese male with follicular lymphoma and renal pelvic carcinoma presented with fever and cough, testing positive for SARS-CoV-2 via PCR. Chest CT revealed ground-glass opacities. Initially, his symptoms improved with a 10-day course of remdesivir (RDV), but they recurred. On day 42, a second 10-day course of RDV combined with dexamethasone was initiated; however, symptoms persisted, and his SARS-CoV-2 PCR test remained positive on day 72. Subsequently, a successful treatment regimen of 10 days of RDV followed by five days of molnupiravir (MOL) was administered. This study represents the first reported case of persistent SARS-CoV-2 infection successfully treated with sequential therapy transitioning from RDV to MOL, without extending the treatment duration.

Indexed as

molnupiravirprolonged covid-19sars-cov-2sars-cov-2 infectionsubsequent antiviral therapy

Identifiers

PMID39816292
PMCPMC11732614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.